Opthea (OPT) said Tuesday it has appointed Parisa Zamiri as its chief medical officer, effective Oct. 7, and Tom Reilly as its chief financial officer, effective Oct. 28.
Zamiri most recently served as Complement Therapeutics' medical chief while Reilly was previously the CFO of Amarin (AMRN).
The company said it is continuing to prepare for the phase 3 topline data readouts of its lead product candidate sozinibercept, with readouts from its COAST study anticipated in early Q2 2025 and from its ShORe trial in mid-2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。